Supplementary materials: Cost–effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma

These are peer-reviewed supplementary materials for the article 'Cost–effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma' published in the Journal of Comparative Effectiveness Research.Table A1: Clinical Inputs.Table A2: Cost Inputs.Table A3: Resource utilization.Table A4: Utility inputs.Aim: To assess the cost–effectiveness of brentuximab vedotin (BV) versus physician’s choice (methotrexate or bexarotene) for treating advanced cutaneous T-cell lymphoma. Materials & methods: A partitioned survival model was developed from the National Health Service perspective in England and Wales. Model inputs were informed by the ALCANZA trial, real-world UK data, published literature or clinical experts. Results: Over the modeled lifetime, BV dominated physician’s choice and provided an additional 1.58 life-years and 1.09 higher quality-adjusted life years with a net cost saving of £119,565. The net monetary benefit was £152,326 using a willingness-to-pay threshold of £30,000/quality-adjusted life year. Results were robust in sensitivity and scenario analyses. Conclusion: BV is a highly cost-effective treatment for advanced cutaneous T-cell lymphoma.